20075-26-7

Basic information

• Product Name: 1-(methoxymethyl)-1H-imidazole
• Synonyms: 1-(methoxymethyl)-1H-imidazole;1-(Methoxymethyl)imidazole;Einecs 243-505-3;1-(Methoxymethyl)
• CAS NO: 20075-26-7
• Molecular Formula: C₅H₈N₂O
• Molecular Weight: 112.12982
• EINECS: 243-505-3
• Mol File: 20075-26-7.mol

Chemical Properties

• Boiling Point: 227.2°Cat760mmHg
• Flash Point: 91.2°C
• Appearance: /
• Density: 1.06g/cm³
• Vapor Pressure: 0.118mmHg at 25°C
• Refractive Index: 1.505
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 6.53±0.10(Predicted)
• CAS DataBase Reference: 1-(methoxymethyl)-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(methoxymethyl)-1H-imidazole(20075-26-7)
• EPA Substance Registry System: 1-(methoxymethyl)-1H-imidazole(20075-26-7)

Safety Data

• Hazardous Substances Data: 20075-26-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(Methoxymethyl)-1H-imidazole is used as a starting material for the synthesis of various heterocyclic compounds, which are important in medicinal chemistry. Its versatile biological activity makes it a valuable component in the development of new medications.
Used in Antimicrobial Applications:
1-(Methoxymethyl)-1H-imidazole is used as an antimicrobial agent for its antifungal, antibacterial, and antiprotozoal activities. Its presence in a variety of synthesized chemicals contributes to the fight against various infections and diseases.
Used in Synthesis of Heterocyclic Compounds:
1-(Methoxymethyl)-1H-imidazole is used as a starting material in the synthesis of a large number of heterocyclic compounds. Its versatility and productivity make it an essential component in the creation of new chemical entities with potential applications in various fields.

InChI:InChI=1/C5H8N2O/c1-8-5-7-3-2-6-4-7/h2-4H,5H2,1H3

Upstream product

• 288-32-4 1H-imidazole 
• 107-30-2 chloromethyl methyl ether 
• 93342-84-8 1-(p-methoxybenzoyl)-3-methoxymethylimidazolium chloride 

Downstream Products

• 90408-23-4 2,5-bis-1-methoxymethylimidazole 
• 160425-46-7 3-Methoxymethyl-3H-imidazole-4-carbaldehyde 
• 49822-73-3 bis-(4-fluoro-phenyl)-(1-methoxymethyl-1H-imidazol-2-yl)-methanol 
• 49822-76-6 (1-methoxymethyl-1H-imidazol-2-yl)-phenyl-(3-trifluoromethyl-phenyl)-methanol 
• 49822-77-7 (1-methoxymethyl-1H-imidazol-2-yl)-phenyl-(4-trifluoromethyl-phenyl)-methanol 
• 49822-97-1 bis-(2,4-dichloro-phenyl)-(1-methoxymethyl-1H-imidazol-2-yl)-methanol 
• 1007596-37-3 1-[1-(methoxymethyl)-1H-imidazol-2-yl]ethanone 
• 1333378-11-2 C₄₁H₃₅BrN₈O₆S₂ 
• 1333378-12-3 C₃₁H₃₁N₇O₄S₂ 
• 1333378-30-5 C₃₆H₃₉N₇O₆S₂ 
• 1333378-21-4 C₂₉H₂₇N₃O₄S₂ 
• 1094172-58-3 C₁₁H₁₃BN₂O₃S 
• 1094172-73-2 C₄₃H₄₆N₄O₉S₃ 
• 1094172-72-1 C₃₆H₄₀N₄O₇S₂ 

Relevant articles and documents

Assembly of the active center of organophosphorus hydrolase in metal-organic frameworks: Via rational combination of functional ligands

Different from popular mimics of bimetallic nuclear centers bridged by a hydroxide, a total coordination sphere of the active center of organophosphorus hydrolase was assembled in metal-organic frameworks by rational design and combination of ligands, which resulted in efficient destruction of nerve agent stimulants without a base as a co-catalyst.

Synthetic studies on dragmacidin D: Synthesis and assembly of three fragments towards an advanced intermediate

We report herein the approach to the key advanced intermediate in the synthesis of the bioactive marine natural product dragmacidin D. By employing a modular synthesis strategy of three fragments (5, 7, and 8), the advanced intermediate 3 has been successfully synthesized in 2.5% yield over 15 steps by starting from nitrotoluene 20. The synthesis also involves sequential cross-coupling reactions, namely Sonogashira and Suzuki-Miyaura reactions, so that various analogues can be efficiently synthesized, which will allow the study of structure-activity relationships of dragmacidin D.

BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES

The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of using the compound, compositions and combinations in the treatment of the diseases.

N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Aminothiazole compounds with N-containing cycloalkyl at the 2-amino position which are represented by the Formula (I), or a pharmaceutically acceptable prodrug of said compound, or pharmaceutically acceptable salt of said compound, modulate and/or inhibit the cell proliferation and activity of protein kinases.

Arylsulfonamidobenzylic compounds

Arylsulfonamidobenzyl alcohols, amines and sulfonamides are provided which are useful in treating lipid disorders, metabolic diseases and cell-proliferative diseases.

1,2,3-Benzothiadiazole derivatives

Novel 1,2,3-benzothiadiazole derivatives of the formula STR1 in which Het has the meanings set forth in the specification, and addition products thereof with an acid or metal salt are very effective for the control of undesired microorganisms. Novel intermediates of the formulae STR2 in which Het1 and R5 have the meanings given in the specification.

Chloropyridylcarbonyl derivatives

Novel chloropyridylcarbonyl derivatives of the formula STR1 in which Het is STR2 n is 1 or 2, R1 is hydrogen, optionally substituted C1-6 alkyl, optionally substituted C2-6 alkenyl, optionally substituted C3-6 alkynyl, optionally substituted phenyl or optionally substituted pyrimidinyl, and R2 and R3, independently of each other, are hydrogen or C1-4 alkyl, and acid addition salts and metal salt complexes thereof, are outstandingly active as microbicides.

Camptothecin and minor-groove binder hybrid molecules: Synthesis, inhibition of topoisomerase I, and anticancer cytotoxicity in vitro

The synthesis, characterization, inhibitory activity against topoisomerase I, and biological evaluation of a series of 14 camptothecin derivatives of polypyrrolecarboxamide (lexitropsin) conjugates of two structural classes: (A) camptothecin-NHCO-lexitropsin 44-51 and (B) camptothecin-CONH-lexitropsin 38-43 are described. All 16 compounds tested, 14 conjugates plus two functionalized camptothecin controls, inhibit topoisomerase I in the concentration range 1.12-16.6 μM that divide into three distinct categories based on activity. The most active enzyme inhibitors belong to structure class A with either cationic dimethylaminium or neutral amide end groups. Generally class B conjugates are less effective in inhibiting topoisomerase I. Cytotoxic potencies of the drugs was tested against four representative human tumor cell lines: SKOV3, SKLVB, HT29, and KB. All 16 drugs gave measurable IC50 values against the KB cell line and fell into two categories with IC50 values of 0.049-0.66 μM (largely structure class B) and 1.0-48 μM (largely class A). Thus the class B conjugates, while less potent against the enzyme, contain two of the most potent drugs, 38 and 39, against KB cell lines. In contrast, in the case of the cell lines SKOV3 and HT29 there was a general correlation between the better topoisomerase inhibitors and their cell cytotoxicities.

Cyclopropylpyrroloindole-oligopeptide anticancer agents

The invention is directed to novel cyclopropylpyrroloindole-oligopeptide compounds which are useful as anticancer agents. The novel cyclopropylpyrroloindole-oligopeptide compounds have the following general structure: STR1 wherein, Het1 and Het2 are individually selected from the group consisting of pyrrole, imidazole, triazole, thiophene, furan, thiazole, oxazole and pyrazole, R is selected from the group consisting of a valence bond; a C1 -C6 alkyl; a C2 -C6 alkenyl; a C2 -C6 alkynyl; and an ortho, meta or para linked aromatic group, A is selected from the group consisting of a C1 -C6 alkyl group; an amidine or derivative thereof; a guanidine; a secondary, tertiary or quaternary ammonium salt; and a sulfonium salt, n is 0 to 3, and m is 0 to 3.